InvestorsHub Logo
Followers 58
Posts 1635
Boards Moderated 0
Alias Born 11/14/2012

Re: None

Thursday, 08/25/2016 2:45:37 PM

Thursday, August 25, 2016 2:45:37 PM

Post# of 69
Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5.84 million shares. Insiders had indicated on buying up to $40 million of the IPO. Protagonist Therapeutics plans to list on the Nasdaq under the symbol PTGX. Leerink Partners, Barclays and BMO Capital Markets acted as lead managers on the deal.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTGX News